Highly efficient and low-cost single-cell culture platform for unbiased analysis of human memory B cell repertoire and antibody discovery
The SARS-CoV-2 pandemic underscored the need for innovative approaches to study humoral immunity and isolate monoclonal antibodies (mAbs) with diagnostic and therapeutic potential. Current methods for repertoire analysis at the clonal level require large-scale recombinant mAb production, limiting accessibility and delaying functional insight. We developed a single-cell culture (SCC) platform that enables profiling of human memory B cells and direct recovery of functional mAbs. Using samples from COVID-19 convalescent and vaccinated donors, we optimized SCCs with NB21 feeder cells, R848, and IL-2, achieving efficient clonal expansion and antibody secretion in short-term cultures. Screening and pseudovirus neutralization assays were performed directly with culture supernatants, bypassing the need for early recombinant antibody production. Antigen-baited cytometry sorting enriched spike-specific memory B cells by ∼30-fold. Among 592 isolated mAbs, 53% bound the Wuhan spike, targeting the receptor-binding domain (28%), N-terminal domain (15%), or other regions (57%). Cross-reactivity analysis revealed that 40% of anti-spike mAbs recognized all tested variants of concern. VH/VL sequencing uncovered convergent rearrangements, including public V3-30 and V3-53/V3-66 clones, consistent with global findings. Two public receptor-binding domain-specific antibodies demonstrated broad neutralization when produced recombinantly. Together, these results validate the SCC system as a streamlined approach for unbiased repertoire analysis and functional mAb isolation. More broadly, the platform provides a practical framework for linking B cell clonal composition with antigen specificity and serum antibody responses. By reducing costs and simplifying workflows, it expands opportunities for antibody discovery and immunoepidemiological studies, fostering wider global participation in therapeutic antibody research.
Authors
- João Hermínio Martins da Silva (ORCID: https://orcid.org/0000-0003-1534-9857)
- Carlena Navas
- Gabriel D. Victora (ORCID: https://orcid.org/0000-0001-8807-348X)
- Bárbara Luísa Soares (ORCID: https://orcid.org/0000-0002-7513-3399)
- Marcela Sabino Cunha (ORCID: https://orcid.org/0009-0000-0913-1347)
- Marcelo T. Bozza (ORCID: https://orcid.org/0000-0003-3683-7550)
- Marcele Neves Rocha (ORCID: https://orcid.org/0000-0001-7130-6961)
- Adriana Bonomo (ORCID: https://orcid.org/0000-0002-3938-9514)
- André M. Vale (ORCID: https://orcid.org/0000-0001-7501-2370)
- Terezinha Marta Pereira Pinto Castiñeiras (ORCID: https://orcid.org/0000-0002-4746-6049)
- Juliana Lima Echevarria
- Carolina Lucas
- Luciana Jesus da Costa (ORCID: https://orcid.org/0000-0002-9044-3387)
- Philippe Caloba
- Gustavo Meira de Asis (ORCID: https://orcid.org/0009-0004-2130-1256)
- Gabriela Maciel (ORCID: https://orcid.org/0000-0002-8915-5345)
- Débora L. Oliveira (ORCID: https://orcid.org/0000-0002-7141-7765)
- Amilcar Tanuri (ORCID: https://orcid.org/0000-0002-9420-6143)
- Lucas Rodrigues Tostes
- D. A. Rodrigues
- L. F. Felicori
- Orlando C. Ferreira
- Aline Albuquerque
- Bruno Maia
- Felipe Oliveira
- Manuela C. Emiliano
- Yare Mello
- Bárbara Gabrielle
- Leda R Castilho
- Fernando Castro
- Suyane S Ferreira
- Alberto Nobrega
- Luciana Conde
Institutions
- Universidade Federal de Minas Gerais (BR)
- Universidade Federal do Rio de Janeiro (BR)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (BR)
- Fundação Oswaldo Cruz (BR)
- Rockefeller University (US)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1093/jimmun/vkaf305
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00